Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06979362 · ClinicalTrials.gov registry record · Phase 2

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

A Phase 2 study of Heart Failure, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT06979362 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 200 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06979362, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

Conditions Studied

Heart Failure

Interventions

  • DRUG Placebo
  • DRUG CDR132L

Study Locations (20)

California

  • Valley Clinical Trials - Covina
  • UCSD NAFLD Research Center - La Jolla
  • Valley Clinical Trials - Northridge
  • University of California, San Francisco - San Francisco
  • University of California San Francisco UCSF - San Francisco
  • Harbor-UCLA Medical Center - Torrance

Florida

  • Inpatient Research Clinic LLC - Miami Lakes
  • AdventHealth Orlando - Orlando
  • Guardian Research Org LLC - Winter Park

Arizona

  • TMC Hlthcr Clin Res Office - Tucson
  • Pima Heart and Vascular - Tucson

Alabama

  • Univ of Alabama Birmingham - Birmingham

Colorado

  • CPC Clinical Research & Community Health - Aurora

Kentucky

  • UofL Health Care Outpatient - Louisville

Michigan

  • Henry Ford Hospital_Detroit - Detroit

Minnesota

  • University of Minnesota_Minneapolis_1 - Minneapolis

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-06-27
Est. Completion 2028-01-23
Phase Phase 2

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06979362

The ClinicalTrials.gov registry entry for NCT06979362 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06979362 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06979362 about?

NCT06979362 is a clinical study titled "A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy". This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chan...

What is the current status of trial NCT06979362?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-27. Estimated completion is 2028-01-23.

What conditions does trial NCT06979362 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06979362?

The interventions under investigation include: Placebo (DRUG), CDR132L (DRUG).

Who is sponsoring clinical trial NCT06979362?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06979362 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.